Someone wrote an article about three health care stocks that might not do well soon. They used something called RSI to show that these stocks are "overbought," which means they have been bought too much recently and might go down in price. The stocks are Verona Pharma, Catalyst Pharmaceuticals, and Viridian Therapeutics. Read from source...

- The article title is misleading and sensationalized: "Top 3 Health Care Stocks You May Want To Dump This Quarter"
- The article body is poorly written and full of grammatical errors: "As of July 30, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions."
- The article body is confusing and unclear: "The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term."
- The article body is irrelevant and unsupported by evidence: "An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro."
- The article body is biased and lacks objectivity: "Here's the latest list of major overbought players in this sector."
- The article body is incomplete and unconvincing: "Verona Pharma PLC – ADR VRNA
Verona Pharma will report its financial results for the second quarter on Thursday, Aug. 8. The company's stock gained around 46% over the past month and has a 52-week high of $23.72."
- The article body is irrelevant and unsupported by evidence: "VRNA Price Action: Shares of Verona Pharma fell 0.5% to close at $22.61 on Monday."
- The article body is incomplete and unconvincing: "Catalyst Pharmaceuticals Inc CPRX
On July 24, Catalyst Pharmaceuticals entered into an exclusive license, supply and commercialization agreement with Kye Pharmaceuticals for AGAMREE® in Canada. “We are pleased to enter into this agreement with Kye Pharmaceuticals for AGAMREE, marking a pivotal milestone in our strategic initiative to expand the product’s footprint in North America. This collaboration leverages our combined expertise, fortifies our alliance by licensing our second therapeutic rare disease product for Canada, and demonstrates our sustained commitment to patient care,” stated Richard J. Daly, CEO and President of Catalyst."
- The article body is irrelevant and unsupported by evidence: "CPRX Price Action: Shares of Catalyst Pharmaceuticals fell 0.6% to close at $17.48 on Monday."
- The article body is incomplete and un

Bearish
Article's Topic: Health care stocks